Cancer. Cancer immunotherapy is more than a numbers game.
Offringa
Rienk
R
Tumor Immunology Group, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. r.offringa@lumc.nl
D019264:Adoptive Transfer; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use; D000939:Epitopes / Q000276:immunology; D005818:Genetic Engineering; D015316:Genetic Therapy; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D058965:MART-1 Antigen; D008545:Melanoma / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D009363:Neoplasm Proteins / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics* / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D019076:Transgenes
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes; D007376:Interleukin-2; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins; D011948:Receptors, Antigen, T-Cell